PROVIDER NOTIFICATION OF POLICY CRITERIA CHANGE							
POLICY TITLE	POLICY NUMBER	CRITERIA CHANGE	MATERIAL AMENDEMENT	EFFECTIVE DATE	LINK TO FULL POLICY		
Tislelizumab-jsgr (e.g., Tevimbra)	2024068	Coverage criteria updated. FDA labeled indication for gastric cancer added. Off-label indications updated. Continuation criteria for off-label indications added. FDA-labeled indications GASTIC CANCER	No	12/15/2025	https://secure.arkansasbluec ross.com/members/report.as px?policyNumber=2024068		
		 INITIAL APPROVAL: Individual is 18 years of age or older; AND Individual has a diagnosis of gastric cancer; AND Tislelizumab will be used in combination with platinum and fluoropyrimidine-based chemotherapy for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥ 1). (Tevimbra, 2025) CONTINUATION OF THERAPY: Individual continues to meet the initial approval criteria; AND Individual experiences objective benefit from continued treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread. 					
		Off-label indications 1. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCCN 2A); OR 2. Hepatocellular Carcinoma (NCCN 1 and 2A); OR 3. Small Bowel Adnocarcinoma (NCCN 2A); OR 4. Anal Carcinoma (NCCN 2A); OR 5. Head and Neck Cancers:					

	a. Cancer of the Nasopharynx (NCCN 2A); OR b. Very Advanced Head and Neck Cancer (NCCN 2A); OR 6. Gastric Cancer (NCCN 1 and 2A); OR 7. Esophageal and Esophagogastric (NCCN 1 and 2A); OR 8. Rectal Cancer (NCCN 2A); OR 9. Colon Cancer: a. Colon Cancer (NCCN 2A); OR b. Appendiceal Adenocarcinoma (NCCN 2A).			
2020024	HCPCS code J9037 is inactive as of 3/31/2025. This policy will be archived effective 12/15/2025.	No	12/15/2025	https://secure.arkansasbluec ross.com/members/report.as px?policyNumber=2020024
1				
	2020024	2A); OR b. Very Advanced Head and Neck Cancer (NCCN 2A); OR 6. Gastric Cancer (NCCN 1 and 2A); OR 7. Esophageal and Esophagogastric (NCCN 1 and 2A); OR 8. Rectal Cancer (NCCN 2A); OR 9. Colon Cancer: a. Colon Cancer (NCCN 2A); OR b. Appendiceal Adenocarcinoma (NCCN 2A).	2A); OR b. Very Advanced Head and Neck Cancer (NCCN 2A); OR 6. Gastric Cancer (NCCN 1 and 2A); OR 7. Esophageal and Esophagogastric (NCCN 1 and 2A); OR 8. Rectal Cancer (NCCN 2A); OR 9. Colon Cancer: a. Colon Cancer (NCCN 2A); OR b. Appendiceal Adenocarcinoma (NCCN 2A).	2A); OR b. Very Advanced Head and Neck Cancer (NCCN 2A); OR 6. Gastric Cancer (NCCN 1 and 2A); OR 7. Esophageal and Esophagogastric (NCCN 1 and 2A); OR 8. Rectal Cancer (NCCN 2A); OR 9. Colon Cancer: a. Colon Cancer (NCCN 2A); OR b. Appendiceal Adenocarcinoma (NCCN 2A).